Rotavirus vaccine introduction in the Americas: progress and lessons learned
- PMID: 18393604
- DOI: 10.1586/14760584.7.3.345
Rotavirus vaccine introduction in the Americas: progress and lessons learned
Abstract
In Latin America and the Caribbean, rotavirus causes approximately 15,000 deaths, 75,000 hospitalizations, 2 million clinic visits and 10 million cases of rotavirus diarrhea annually. Two safe vaccines are available that are effective in preventing severe illness. To date, seven countries in Latin America (Brazil, Ecuador, El Salvador, Panama, Mexico, Nicaragua and Venezuela) have introduced the vaccine. For successful rotavirus vaccine introduction, the lessons learned re-emphasize the critical need for countries to have precise plans that will ensure technical, programmatic and financial sustainability of vaccine introduction. Of these lessons learned, programmatic feasibility and financial sustainability were particularly challenging for countries that were the first to introduce a rotavirus vaccine.
Similar articles
-
Progress in the introduction of rotavirus vaccine--Latin America and the Caribbean, 2006-2010.MMWR Morb Mortal Wkly Rep. 2011 Dec 2;60(47):1611-4. MMWR Morb Mortal Wkly Rep. 2011. PMID: 22129995
-
Rotavirus vaccines: targeting the developing world.J Infect Dis. 2005 Sep 1;192 Suppl 1:S160-6. doi: 10.1086/431504. J Infect Dis. 2005. PMID: 16088799
-
Global impact of rotavirus vaccines.Expert Rev Vaccines. 2010 Apr;9(4):395-407. doi: 10.1586/erv.10.17. Expert Rev Vaccines. 2010. PMID: 20370550 Review.
-
Rotavirus vaccine: early introduction in Latin America-risks and benefits.Arch Med Res. 2006 Jan;37(1):1-10. doi: 10.1016/j.arcmed.2005.06.004. Arch Med Res. 2006. PMID: 16314179 Review.
-
A critical time for rotavirus vaccines: a review.Expert Rev Vaccines. 2005 Aug;4(4):521-32. doi: 10.1586/14760584.4.4.521. Expert Rev Vaccines. 2005. PMID: 16117709 Review.
Cited by
-
Constructing target product profiles (TPPs) to help vaccines overcome post-approval obstacles.Vaccine. 2010 Apr 1;28(16):2806-9. doi: 10.1016/j.vaccine.2009.09.047. Epub 2009 Sep 25. Vaccine. 2010. PMID: 19782109 Free PMC article. Review.
-
Rotavirus vaccine RIX4414 (Rotarix™): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developing countries.Pharmacoeconomics. 2011 Nov;29(11):989-1009. doi: 10.2165/11207210-000000000-00000. Pharmacoeconomics. 2011. PMID: 21988293 Review.
-
Enhancing the work of the Department of Health and Human Services national vaccine program in global immunization: recommendations of the National Vaccine Advisory Committee: approved by the National Vaccine Advisory Committee on September 12, 2013.Public Health Rep. 2014;129 Suppl 3(Suppl 3):12-85. doi: 10.1177/00333549141295s305. Public Health Rep. 2014. PMID: 25100887 Free PMC article. No abstract available.
-
The burden of pediatric diarrhea: a cross-sectional study of incurred costs and perceptions of cost among Bolivian families.BMC Public Health. 2013 Aug 2;13:708. doi: 10.1186/1471-2458-13-708. BMC Public Health. 2013. PMID: 23915207 Free PMC article.
-
Rotavirus in developing countries: molecular diversity, epidemiological insights, and strategies for effective vaccination.Front Microbiol. 2024 Jan 5;14:1297269. doi: 10.3389/fmicb.2023.1297269. eCollection 2023. Front Microbiol. 2024. PMID: 38249482 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical